S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

IGM Biosciences Stock Price, News & Analysis (NASDAQ:IGMS)

$19.03
+0.03 (+0.16 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$18.74
Now: $19.03
$19.99
50-Day Range N/A
52-Week Range
$16.10
Now: $19.03
$24.57
Volume124,900 shs
Average Volume126,629 shs
Market Capitalization$549.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IGMS
CUSIPN/A
CIKN/A
Phone650-965-7873

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees40
Market Cap$549.80 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IGMS News and Ratings via Email

Sign-up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.


IGM Biosciences (NASDAQ:IGMS) Frequently Asked Questions

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

What price target have analysts set for IGMS?

4 equities research analysts have issued twelve-month price objectives for IGM Biosciences' shares. Their predictions range from $25.00 to $32.00. On average, they anticipate IGM Biosciences' share price to reach $28.25 in the next year. This suggests a possible upside of 48.4% from the stock's current price. View Analyst Price Targets for IGM Biosciences.

What is the consensus analysts' recommendation for IGM Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IGM Biosciences.

Has IGM Biosciences been receiving favorable news coverage?

Media coverage about IGMS stock has trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IGM Biosciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for IGM Biosciences.

Who are some of IGM Biosciences' key competitors?

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Cara Therapeutics (CARA), East West Bancorp (EWBC), E*TRADE Financial (ETFC), Enphase Energy (ENPH), Dropbox (DBX), Cronos Group (CRON), Constellation Pharmaceuticals (CNST), Celldex Therapeutics (CLDX), Bank7 (BSVN) and Atreca (BCEL).

Who are IGM Biosciences' key executives?

IGM Biosciences' management team includes the folowing people:
  • Mr. Fred M. Schwarzer, CEO, Pres & Director (Age 66)
  • Mr. Misbah Tahir, Chief Financial Officer (Age 44)
  • Dr. Bruce A. Keyt, Chief Scientific Officer (Age 66)
  • Ms. Suzette Tauber, VP of HR (Age 56)
  • Mr. Daniel Chen, Chief Medical Officer (Age 50)

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

When does the company's quiet period expire?

IGM Biosciences' quiet period expires on Monday, October 28th. IGM Biosciences had issued 10,937,500 shares in its public offering on September 18th. The total size of the offering was $175,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of IGM Biosciences?

Shares of IGMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $19.03.

How big of a company is IGM Biosciences?

IGM Biosciences has a market capitalization of $549.80 million. IGM Biosciences employs 40 workers across the globe.View Additional Information About IGM Biosciences.

What is IGM Biosciences' official website?

The official website for IGM Biosciences is http://igmbio.com/.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-965-7873.


MarketBeat Community Rating for IGM Biosciences (NASDAQ IGMS)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about IGM Biosciences and other stocks. Vote "Outperform" if you believe IGMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel